Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05172687 · ClinicalTrials.gov registry record
The Effect of De-Prescribing Antipsychotics on Health and Quality of Life for People With Dementia
A clinical trial of Alzheimer Disease and Dementia, sponsored by Columbia University.
- Completed
- Registry status
- 336,460
- Enrollment target
- 3
- Study locations
NCT05172687: Completed study of Alzheimer Disease and Dementia, sponsored by Columbia University.
NCT05172687 is a study of Alzheimer Disease and Dementia that has completed, run by Columbia University. The registered enrollment target is 336,460 participants, above the 1,651-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (20279% higher). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05172687, a study of Alzheimer Disease and Dementia, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- 336,460 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study aims to analyze how warning letters sent to physicians prescribing high levels of the antipsychotic quetiapine affected the health and quality of life of their patients with dementia. Using a randomized controlled trial conducted by the Centers for Medicare and Medicaid Services (CMS) in 2015, this secondary study looks at the effects of potential de-prescribing of antipsychotics by study physicians induced by the letters. The central question is whether the intervention led to better health and quality of life outcomes by encouraging more guideline-concordant care and whether changes in physicians' prescription behavior caused unintended harms.
Primary Outcome
Days of quetiapine received during the outcome measurement period
Conditions Studied
Interventions
- BEHAVIORAL Overprescribing letter to attributed physician
- BEHAVIORAL Placebo letter to attributed physician
Study Locations (3)
Massachusetts
- Harvard T.H. Chan School of Public Health - Boston
- National Bureau of Economic Research - Cambridge
New York
- Columbia University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 336,460 participants |
| Start Date | 2015-04 |
| Est. Completion | 2018-12-31 |
What the finished NCT05172687 record still lists
NCT05172687 is an observational study that tracks outcomes without assigning an intervention. Its 336,460 participants enrollment target places it among the larger protocols in the corpus, above the 1,651-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (20279% higher).
The record links to 3 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Overprescribing letter to attributed physician is the first listed.
NCT05172687 reports a single indexed study location in Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT05172687 about?
NCT05172687 is a clinical study titled "The Effect of De-Prescribing Antipsychotics on Health and Quality of Life for People With Dementia". This study aims to analyze how warning letters sent to physicians prescribing high levels of the antipsychotic quetiapine affected the health and quality of life of their patients with dementia. Using a randomized controlled trial conducted by the Centers for Medicare and Medicaid Services (CMS) in ...
What is the current status of trial NCT05172687?
This trial is currently completed. The enrollment target is 336,460 participants. The study started on 2015-04. Estimated completion is 2018-12-31.
What conditions does trial NCT05172687 study?
This clinical trial studies the following conditions: Alzheimer Disease, Dementia, Prescribing, Off-Label.
What interventions are being tested in trial NCT05172687?
The interventions under investigation include: Overprescribing letter to attributed physician (BEHAVIORAL), Placebo letter to attributed physician (BEHAVIORAL).
Who is sponsoring clinical trial NCT05172687?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05172687 being conducted?
This trial has 3 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05172687's enrollment target sits among peer trials
336,460 1st of 306 higher than 306 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05668637 · 318,542 participants
Evaluation and Further Development of an Artificial Intelligence-based Algorithm for Clinical Decision Support
- NCT05365048 · 301,201 participants · NA
Provider Recommendation and HPV Vaccination
- NCT02280733 · 300,000 participants
A Real-World Registry of Chronic Wounds and Ulcers
- NCT06694181 · 300,000 participants
Safe and Explainable AI
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia